Saturday 17 October 2026
Export HCWB’s income statement to Excel — free account
HCW Biologics Inc.
HCWB Healthcare Biotechnology
HCW Biologics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $54,200.00, down 97.9% from fiscal 2024. In the quarter to June 2026, revenue grew 1,954.6%, EPS grew 71.6%, free cash flow fell 20.8% and total debt fell 3.34%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
1.24
0.01
+0.81%
Follow HCWB
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
3 | 3 | — | — | — | — | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | — | — |
Altman Z-Score |
(8.83) | (8.45) | (4.68) | 2.91 | — | — | — | — |
P/S ratio |
37.55 | 6.74 | 15.17 | 10.45 | — | 0.00 | — | — |
Altman Z″-Score (non-manufacturers) |
(22.93) | (22.77) | (13.72) | 3.21 | — | (1.88) | — | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | — | — |
Beneish M-Score |
(9.28) | (6.27) | 3.67 | — | — | — | — | — |
P/Operating CF |
(0.61) | (6.11) | (11.07) | (18.53) | — | (31.30) | — | — |
P/B ratio |
0.74 | 0.00 | 3.20 | 1.88 | — | 0.00 | — | — |
Price to Tangible BV |
0.74 | 0.00 | 3.20 | 1.88 | — | 0.00 | — | — |
EV/Sales |
133.75 | 10.26 | 16.18 | 6.63 | — | 0.00 | — | — |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | — | — |
EV/Operating CF |
(0.54) | (1.85) | (2.04) | (4.29) | — | (2.96) | — | — |
EV/FCF |
(0.53) | (1.82) | (1.60) | (2.16) | — | (2.90) | — | — |
Quick Ratio |
0.09 | 0.18 | 0.59 | 10.99 | 15.87 | 10.94 | 6.90 | — |
Current Ratio |
0.11 | 0.19 | 0.73 | 11.52 | 17.44 | 12.14 | 7.53 | — |
Net Debt/EBITDA |
(0.40) | (0.32) | (0.11) | 1.79 | 2.86 | 1.50 | 1.06 | — |
Debt/Assets |
27.77% | 45.28% | 22.11% | 13.69% | 0.00% | 3.68% | 0.00% | 0.00% |
Debt/Equity |
2.46 | (2.02) | 0.47 | 0.17 | 0.00 | (0.03) | 0.00 | — |
Asset Turnover |
0.00 | 0.09 | 0.08 | 0.13 | 0.00 | 0.32 | 0.00 | — |
Operating CF/Net income |
0.60 | 0.47 | 0.90 | 0.70 | 0.85 | 1.47 | 0.87 | — |
Capex/Depreciation |
0.00 | (0.22) | (5.46) | (14.31) | (0.09) | (0.33) | 0.00 | — |
Interest Coverage |
(15.58) | (45.02) | (90.87) | (119.01) | — | (261.19) | (203.46) | — |
| 1,113.43% | (897.37%) | (98.23%) | (33.63%) | (74.62%) | 53.60% | 58.97% | — | |
| (81.45%) | (102.21%) | (66.37%) | (29.71%) | (37.33%) | (55.56%) | (154.63%) | — | |
ROIC |
(107.94%) | (819.04%) | (99.40%) | (80.03%) | (57.70%) | 0.00% | 0.00% | — |
Return on Tangible Assets |
(1,060.53%) | 2,942.07% | (138.02%) | (35.55%) | (32.75%) | (55.43%) | (86.80%) | — |
Average Days of Receivables |
216.85 | 82.79 | 197.26 | 22.68 | 0.00 | 222.57 | — | — |
Research and Development Expense of Revenue |
10,042.25% | 248.91% | 270.12% | 138.92% | 0.00% | 176.96% | 0.00% | — |
Selling, General and Administrative Expense of Revenue |
14,209.04% | 265.56% | 238.56% | 123.87% | 0.00% | 65.10% | 0.00% | — |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
1,418.08% | 39.31% | 35.32% | 16.66% | 0.00% | 0.53% | — | — |
Graham Net Nets |
(9.55) | (1.81) | (0.20) | 0.35 | — | (0.85) | — | — |
Graham Number |
0.00 | 363.65 | 0.00 | 0.00 | — | 3,057.84 | — | — |
Earnings Yield |
(1,214.07%) | (131.14%) | (58.32%) | (21.38%) | — | (38.19%) | — | — |
Free Cash Flow Yield |
(669.68%) | (83.71%) | (66.61%) | (29.42%) | — | (28.82%) | — | — |
Revenue per Share |
0.16 | 15.87 | 18.98 | 45.02 | 0.00 | 208.11 | 0.00 | — |
Operating CF per Share |
(38.29) | (87.99) | (150.39) | (69.57) | (140.35) | (529.51) | (0.18) | — |
Capex per Share |
0.00 | (1.62) | (41.43) | (68.82) | (0.60) | (9.48) | 0.00 | — |
Free Cash Flow per Share |
(38.29) | (89.60) | (191.83) | (138.39) | (140.96) | (538.98) | (0.18) | — |
Cash per Share |
5.58 | 28.91 | 24.02 | 214.75 | 469.49 | 429.23 | 0.20 | — |
Shareholders Equity per Share |
7.91 | (41.87) | 89.92 | 250.69 | 654.64 | (848.65) | 0.25 | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
7.91 | (41.87) | 89.92 | 250.69 | 654.64 | (848.65) | 0.25 | — |
Free Cash Flow |
(13.39) | (14.49) | (28.72) | (20.66) | (11.02) | (10.62) | (6.77) | — |
Working Capital |
(18.78) | (23.93) | (2.34) | 31.11 | 38.16 | 11.15 | 6.96 | — |
Capital Expenditures |
— | (0.26) | (6.20) | (10.28) | (0.05) | (0.19) | (1.46) | — |
Net Current Asset Value |
(19.47) | (31.31) | (8.65) | 24.69 | 38.16 | (19.97) | 6.96 | — |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | — | — |
Capex to Sales |
0.00 | 0.10 | 2.18 | 1.53 | 0.00 | 0.05 | — | — |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | — | — |
| Other line items | ||||||||
Depreciation/Fixed assets |
0.05 | 0.05 | 0.06 | 0.07 | 0.49 | 0.35 | 0.21 | — |
Cash ROIC |
(116.18%) | (124.94%) | (122.93%) | (27.22%) | (12.54%) | 137.98% | (41.36%) | — |
Accounts Receivable Turnover |
0.18 | 2.42 | 2.91 | 24.41 | 0.00 | 3.11 | — | — |
Accounts Payable Turnover |
0.00 | 0.11 | 0.62 | 5.70 | 2.87 | 0.00 | 1.54 | — |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | — |
Average Days of Payables |
110,537.81 | 5,071.10 | 986.69 | 108.22 | 150.20 | 0.00 | 339.47 | — |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | — |
Average Receivables |
0.31 | 1.06 | 0.98 | 0.28 | 1.32 | 1.32 | — | — |
Average Payables |
17.74 | 14.25 | 3.70 | 0.72 | 0.19 | 0.27 | 0.27 | — |
Average Assets |
27.38 | 29.38 | 37.66 | 50.16 | 34.46 | 12.73 | 5.03 | — |
Average Common Equity |
(2.00) | 3.35 | 25.45 | 44.31 | 17.24 | (13.20) | (13.20) | — |
Columns are period end dates